Back to top
more

Harmony Biosciences (HRMY)

(Real Time Quote from BATS)

$32.83 USD

32.83
77,325

-0.24 (-0.73%)

Updated Nov 19, 2024 10:54 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Strength Seen in Harmony Biosciences Holdings, Inc. (HRMY): Can Its 5.1% Jump Turn into More Strength?

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Why Harmony Biosciences (HRMY) Stock Might be a Great Pick

by Zacks Equity Research

Harmony Biosciences (HRMY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 850% and 3.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Harmony Biosciences Holdings, Inc. (HRMY) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Albireo Pharma (ALBO) Stock Jumps 11%: Will It Continue to Soar?

by Zacks Equity Research

Albireo Pharma (ALBO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 42.50% and 7.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Beats Q1 Earnings Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 96.88% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Berkeley Lights, Inc. (BLI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -4% and 5.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 88.89% and 1.81%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harmony Biosciences Holdings, Inc. (HRMY) Surges 10.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Harmony Biosciences Holdings, Inc. (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks.com featured highlights include: Alpha and Omega Semiconductor, Preferred Apartment Communities, Hut 8 Mining, GCM Grosvenor and Harmony Biosciences

by Zacks Equity Research

Zacks.com featured highlights include: Alpha and Omega Semiconductor, Preferred Apartment Communities, Hut 8 Mining, GCM Grosvenor and Harmony Biosciences

Shrabana Mukherjee headshot

5 Stocks for Higher Returns as Analysts Initiate Coverage

by Shrabana Mukherjee

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like Alpha and Omega (AOSL), Preferred Apartment (APTS), Hut 8 Mining (HUT), GCM (GCMG) & Harmony Biosciences (HRMY).

Axsome (AXSM) Begins Late-Stage Sleep Disorder Study on AXS-12

by Zacks Equity Research

Axsome (AXSM) is developing AXS-12 as a potential treatment for narcolepsy. The company initiates enrollment in a phase III study evaluating AXS-12.

Axsome's (AXSM) Migraine Drug AXS-07 NDA Gets FDA Acceptance

by Zacks Equity Research

Axsome (AXSM) is seeking approval for its key pipeline candidate, AXS-07, as a potential acute treatment for migraine.

Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag

by Zacks Equity Research

The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.

Kinjel Shah headshot

Drug/Biotech Stock Q1 Earnings on May 10: CPRX, PRTA & More

by Kinjel Shah

Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.